Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px
Person › Details

Gregory Byram (Nuclea Biotechnologies Inc.)

Byram, Gregory (Nuclea Biotechnologies 201502– Senior Technologist Clinical Proteomic Discovery before Thermo BRIMS)


Organisation Organisation Nuclea Biotechnologies Inc.
Products Product proteomics
  Product 2 clinical proteomic test

Nuclea Biotechnologies, Inc.. (2/19/15). "Press Release: Prominent Proteomics Business Development Team Joins Nuclea. Commercialization and Proteomics Expert Dr. Mary Lopez Will Be Appointed COO". Pittsfield, MA.

Nuclea Biotechnologies, Inc. announced today that a team of six leading proteomics development and business support specialists from the Thermo Fisher Scientific Inc.’s premier BRIMS Center in Cambridge, MA will be joining Nuclea. The BRIMS center provides customers with commercial applications of clinical assays and supports the sales and marketing efforts of the Thermo Fisher Mass Spectrometry division. Thanks to their combined experience and expertise in product development and commercial sales, the addition of these key members to the company’s leadership team will serve to accelerate the roll-out of Nuclea’s products.

The team is led by Dr. Mary Lopez, who will be appointed Chief Operating Officer (COO) of Nuclea. Her prime focus will be on the market introduction of Nuclea's broad array of FDA approved tests and other CLIA based tests. As COO, she will be building upon her experience in developing and marketing metabolic syndrome diagnostics products, such as the Mass Spectrometry Insulin identification assay, to develop Nuclea’s ongoing rollout of its diagnostic product line.

Most recently, Dr. Lopez served as the Director of the BRIMS Center where she managed and brought to market a large array of biomarker applications that helped to fuel the growth of Thermo Fisher instrument business. Previously, she has held positions as Strategic Collaborations Leader and Analytical Proteomics Business Leader at PerkinElmer Life and Analytical Sciences in Waltham, MA and Executive Vice President of Proteomics Research and Development at Proteome Systems. Dr. Lopez continues to publish extensively in the field of Proteomics and serves on the scientific advisory board of the Clinical Proteomics Research Center at Massachusetts General Hospital.

The esteemed members of Dr. Lopez’s team joining Nuclea in the capacity of accelerating commercialization and expanding biomarker validation for clinical use include:

Bryan Krastins, M.B.A., Director of CLIA Proteomic Lab – Mr. Krastins will be responsible for all CLIA clinical laboratory management, accreditation, and validation of assays.

Maryann Vogelsang, Ph.D., Director of Bioinformatics –Dr. Vogelsang will manage the bioinformatics structure of the CLIA clinical laboratory and biomarker development.

Gregory Byram, Senior Technologist, Clinical Proteomic Discovery –Mr. Byram will support all clinical validation and biomarker development.

Additionally, Nuclea will bring on a Clinical Proteomics Manager, to manage the development and commercialization of new biomarker discoveries in proteomics, and a Director of Business and Biomarker Development, who will be responsible for interacting with customers for all proteomic products in the Nuclea portfolio and will be responsible for all biomarker development and clinical commercial validations.

“The addition of Dr. Mary Lopez and her team will accelerate Nuclea’s commercialization efforts. We hope to capitalize on Dr. Lopez’s background in business development, as well as her experience utilizing application science in marketing, to increase customer uptake of Nuclea’s product line,” said Patrick Muraca, President and CEO of Nuclea Biotechnologies. “Nuclea has been fortunate to leverage the expertise of Dr. Walter Carney as Chief Scientific Officer, and we welcome the opportunity to add the prowess of our new team members to complement that of our current management and business development executives.”

“We are excited to broaden and bring to market the spectrum of diagnostics already offered by Nuclea, while contributing to the evolution of a biotech company on the frontlines of innovation in personalized medicine,” said Dr. Mary Lopez, COO of Nuclea Biotechnologies. “I look forward to the opportunity to engage with Nuclea’s customers directly in order to determine how our products can best serve their needs.”

Dr. Lopez and her team will begin work on developing and commercializing new tests and assays for biomarkers with a focus on Type II diabetes and other metabolic diseases at Nuclea’s Cambridge facilities. Their integration into the leadership of Nuclea’s CLIA laboratory will be fundamental in bolstering the company’s commercialization strategy through the establishment of new sales opportunities.

Nuclea Biotechnologies, Inc. -- is headquartered in Pittsfield, Massachusetts with additional operations in Worcester and Cambridge, Massachusetts. Nuclea has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung, and prostate cancer, as well as for diabetes and other metabolic syndromes. Nuclea also performs research leading to novel molecular oncology companion diagnostics for the pharmaceutical and biotechnology industries.


Record changed: 2016-03-19


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture [LSUS] – The Business Web Portal 600x60px

» top